EGFR and non-small cell lung carcinoma: The studies examining EGFR-mutated NSCLC patients treated with erlotinib, first-generation EGFR-TKIs, have shown that the presence of malignant PE is associated with a shorter progression-free survival (PFS) and overall survival (OS) [6, 7].